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1. Introduction 
Infectious diseases continue to heavily burden our global society. Endemic and epidemic 
malaria results in severe disease in an estimated half-a-billion people each year, and causes 
over 1.5 million deaths annually. Although progress has been made in the prevention and 
treatment of falciparum malaria infections, more effective, tolerable and affordable therapies 
are urgently needed. This deadly parasite displays unique human tropism, and the 
development of novel intervention strategies have been hampered by the lack of robust, cost 
effective, and predictive animal models that accurately reproduce the hallmark of human 
infections. While rodents and non-human primates have been employed in biomedical 
research and drug/vaccine development, they often do not yield reliable preclinical results 
that translate into effective human treatments. “Humanized” mice have recently emerged as 
powerful tools in the investigation of human diseases (Legrand et al., 2006; Manz, 2007; 
Shultz et al., 2007). These are amenable animal models transplanted with various kinds of 
human cells and tissues (and/or equipped with human transgenes) that may be ideally 
suited for direct investigation of human infectious agents such as malaria. Despite the 
challenges, humanized mouse technology has made rapid progress over the last few years, 
and it is now possible to achieve significant levels of human chimerism in various hosts, 
organ/tissues, particularly the immune systems, liver and muscles. Such humanized mice 
provide a new opportunity to perform preclinical studies of intractable human malaria 
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parasite. However, the relevance of Plasmodium falciparum-infected humanized mice for 
malaria studies has been questioned because of the low percentage of mice in which the 
parasite develops. Malaria caused by Plasmodium falciparum is difficult to model in the 
laboratory because of the specificity of this parasite for its human host, the complexity of its 
life cycle and the substantial diversity of parasite strains. Consequently, most experimental 
in vivo studies on malaria have heavily relied on different combinations of various murine 
strains and Plasmodium spp. of rodent (Carlton et al., 2001; Hernandez-Valladares et al., 
2005) but biological differences between parasite species remain a major limitation. For 
example, there are many indications that in human cerebral malaria, the preferential 
sequestration of parasitized erythrocytes in the brain capillaries is the central precipitating 
step (Medana and Turner, 2006), whereas this phenomenon is much less evident in rodent 
models (Lou et al., 2001). 
Limitations of experimental models have also hampered the evaluation of the impact of new 
drugs or vaccines prior to clinical trials. During the preclinical screening of a new drug, its 
activity has to be evaluated first against the development of P. falciparum in vitro, then 
against the infection of a rodent Plasmodium in a mouse model and, finally, against P. 
falciparum infection in a monkey model (Fidock et al., 2004) or in a humanized mouse model. 
1.1 Perspectives 
The stability, reproducibility and long-standing tendency of parasitaemia in the developed 
humanized model based on NOD/SCID/IL2Rγ-null mouse (NSG), a mouse strain with 
profoundly deficient adaptive and innate immunity (NSG-IV model) might be validated by 
selecting artesunate resistant mutants of P. falciparum through prolonged exposure of the 
parasite to increasing levels of the drug. 
2. The development of humanized mice 
Advances in the ability to generate humanized mice have depended on a systematic 
progression of genetic modifications to develop immunodeficient host mice. Three main 
breakthroughs have occurred in this field (TIMELINE). First, the discovery of the Prkdcscid 
(protein kinase, DNA activated, catalytic polypeptide; severe combined immunodeficiency, 
abbreviated scid) mutation in CB17 mice (Bosma et al., 1983) was soon followed by the 
observation that human PBMCs (Mosier et al., 1988), fetal haematopoietic tissues (McCune 
et al., 1988) and HSCs (Lapidot et al., 1992) could engraft in these mice. However, 
engraftment occurred at only a very low level, and the engrafted human cells failed to 
generate a functional human immune system. The limitations impeding human-cell 
engraftment in CB17-scid mice include the spontaneous generation of mouse T and B cells 
during aging (known as leakiness) and high levels of host natural killer (NK)-cell and other 
innate immune activity, which limit the engraftment of the human hematopoietic 
compartment (Greiner et al., 1998). The scid mutation also results in defective DNA repair 
and, consequently, an increase in radio sensitivity. Targeted mutations at the recombination-
activating gene 1 (Rag1) and Rag2 loci prevent mature T- and B-cell development in the mice 
but do not cause leakiness or radio sensitivity. However, these mice retained high levels of 
NK-cell activity and had limited engraftment of human HSCs (Greiner et al., 1998; 
Mombaerts et al., 1992; Shinkai et al., 1992). 
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The second breakthrough was the development of immunodeficient non-obese diabetic 
(NOD)-scid mice (Shultz et al., 1995). Crossing the scid mutation onto different strain 
backgrounds led to the observation that NOD-scid mice supported higher levels of 
engraftment with human PBMCs than did any of the other strains that were tested, 
including C3H/HeJ-scid and C57BL/6-scid mice (Hesselton et al., 1995). Furthermore, it was 
observed that NK-cell activity, which is one of the main impediments to the engraftment of 
human haematopoietic cells (Christianson et al., 1996), was lower in NOD-scid mice than in 
CB17-scid mice (Shultz et al., 1995). NOD-scid mice also have additional defects in innate 
immunity that allow higher levels of human PBMC (Hesselton et al., 1995) and HSC (Lowry 
et al., 1996; Pflumio et al., 1996) engraftment. Incremental improvements in the extent of 
human-cell engraftment as a result of the development of new genetic variations of NOD-
scid mice occurred over the following 10 years (TIMELINE), but the use of humanized NOD-
scid mice as a model for human immunity remains limited by their relatively short life span, 
and the residual activity of NK cells and other components of innate immunity, which 
impedes the engraftment of the human lymphoid compartment.  
The third breakthrough was the humanization of immunodeficient mice homozygous for 
targeted mutations at the interleukin-2 receptor (IL-2R) Ǆ-chain locus (Il2rg; also known as 
the common cytokine-receptor Ǆ-chain, Ǆc) (Ishikawa et al., 2005; Ito et al., 2002; Shultz et al., 
2005;Traggiai et al., 2004). These mice support greatly increased engraftment of human 
tissues, HSCs and PBMCs compared with all previously developed immunodeficient 
humanized mouse models. The IL-2R Ǆ-chain is a crucial component of the high-affinity 
receptors for IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21, and it is required for signaling through 
these receptors (Sugamura et al., 1996). The absence of the IL-2R Ǆ-chain leads to severe 
impairments in T- and B-cell development and function, and completely prevents NK-cell 
development (Cao et al., 1995; DiSanto et al., 1995; Ohbo et al., 1996). 
3. Optimization of immunosuppression protocols: Engraftment of  
P. falciparum in humanized mice  
After an obtainment of proliferation of Theileria sergenti in scid mouse grafted with bovine-
RBC (Tsuji et al., 1992), several studies raised the possibility of obtaining P. falciparum in 
immune deficient mice grafted with huRBCs (Badell et al., 2000; Moore et al., 1995; Tsuji et 
al., 1995). The researchers used different strategies to improve parasite survival considering 
the fast clearance of the parasite in few hours after being inoculated. Moore et al tried to 
adapt parasite in vitro partially in the serum of scid mice in place of human serum before 
being inoculated into the mouse (Moore et al., 1995). A concentration of mouse serum higher 
than 5% was found toxic for the parasite in culture. In this study, the NOD/scid mice were 
intraperitoneally infected with 1% adapted parasite followed by 1 ml huRBCs injection 
everyday. The parasite survival lasting up to 10 days was achieved with this protocol. 
Although splenectomized mice had shown an improvement of parasite growth (>15 days), 
variations in the parasitaemia from one mouse to another was detected. Another research 
group (Badell et al., 1995) developed another strategy of P. falciparum survival in the 
immunodeficient mice. They also noted that parasite inoculated through i.p. route into the 
scid mouse was eliminated in few hours from the circulation. Moreover, mouse serum 
added in in vitro cultures did not show any toxicity to parasite growth and parasite survival 
was observed even at 10% serum. This experiment further confirmed the important role of 
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residual innate immune effectors of mice in the clearance of parasite. The efforts have been 
made to control innate immune effectors by various means such as irradiation and 
cyclophosphamide treatment however with limited success. This group was able to establish 
an immunomodulatory protocol for BXN mouse to deplete innate immune regulatory cells 
and could achieve an average of 0.1% parasitaemia. This immunomodulatory protocol 
comprised of an i.p. injection of 0.2 ml of dichloro-methylene-diphosphonate (CL2MDP) 
loaded liposome once per week to destroy the murine macrophages in conjunction with an 
administration of an anti-PMN monoclonal antibody at every 5th day to block the 
polymorphonuclear cells and also the injection of 1 ml of huRBCs & AB+ human serum in 1 
ml of 10%-RPMI every day. Tsuji et al, used splenectomized scid mice and administered 
huRBCs by intravenous route from day 1 to 5. As from day 1 to 4 mice received an 
intraperitoneal injection of 500μl of human serum as well as a subcutaneous injection of 
an anti-mouse RBC antibody to replace murine RBC by huRBCs. Afterwards, the mouse 
was reconstituted with the huRBCs followed by the irradiation, and was also injected with 
1.6-4% parasitized huRBCs through an intravenous route. By employing this protocol 
almost complete substitution of murine RBC by huRBCs was achieved (Tsuji et al., 1995). 
Until recently, immunomodulatory protocol (destroying macrophages with CL2MDP-lip 
and blocking PMN with an anti-PMN monoclonal antibody) was applied to the 
NOD/scid mice (Moreno Sabater et al., 2005). Moreover, a comparative study was carried 
out to show differences in the capabilities of P. falciparum survival in BXN and NOD/scid 
mice using the protocol with two intraperitoneal infections (i.e. primary infection on 3rd 
day and secondary infection on 18th day) and with the injection of immunosuppressors 
along with fresh huRBCs at every three days interval. In brief NOD/scid mouse allowed a 
better development of the parasite for 35 days with 75% infectivity compared to only 8% 
with BXN mice. In the BXN mouse strain the parasite could grow until day 7 post second 
infections followed by a gradual decrease in parasitaemia. On the contrary NOD/scid 
mice showed 0.25% average parasitaemia until day 17 post second infection. Therefore 
this protocol with NOD/scid mice showed an improvement of parasite survival (Moore et 
al., 1995). Interestingly, this protocol does not imply either the need of splenectomy or in 
vitro adaptation of the parasite prior to infection. Recently Inigo et al (Angulo-Barturen et 
al., 2008), developed a murine model (NOD/scidǃ2m-/-) to study falciparum-malaria in 
non-myelodepleted mice grafted with human erythrocytes with considerable success in 
terms of parasitaemia and with 100% infectivity. They claimed to generate in vivo strains of 
P. falciparum able to grow reproducibly in peripheral blood of humanized mouse with out 
using immunosuppressors to deplete murine phagocytes. Despite the significant success 
with this model cumbersome administration of 1ml RBC pellet i.p. everyday and in vitro 
adaptation of falciparum strains prior to infection raise questions over its ideal nature. The 
same group (Jimenez-Diaz et al., 2009) came up with the same protocol applied to 
NOD/SCIDIL-2RǄ-/- strain with slight modifications for the survival of the parasite. 
Therefore to complement the descriptive analysis in humans by an experimental approach 
in a model, we decided to perform in P. falciparum NOD/SCID model a systematic and 
stepwise analysis of innate cell responses and inflammation mediators produced in response 
to the grafting of HuRBC, of P. falciparum, as well as to agents employed to control innate 
defences. The results brought new insights about the role and potency of innate defences 
against human xenografts, such as HuRBC, and human pathogens, such as P. falciparum 
(Arnold et al.).  
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Fig. 1. Chronological events in the development of humanized mouse model 
A main barrier to achieving an improved, workable P. falciparum mouse model is the strong 
pro-inflammatory effect of the parasite itself. In humans the asexual erythrocytic stages of P. 
falciparum are known to result in a systemic inflammatory process that is responsible for 
many of the symptoms of the disease. A second significant practical problem with all 
existing models developed to date is that huRBC are injected by the intra-peritoneal (IP) 
route, which relies on the successful migration of huRBC into the blood stream across the 
peritoneum. This is a process that is not properly understood, and, therefore, prevents any 
rational analysis and further improvement of the model. With these limitations of current 
models in mind, we thought to improve the P. falciparum humanized mouse model, 
particularly in terms of control of inflammatory reactions, and reproducibility of 
parasitemia. We decided to address these issues by using the IV route for huRBC and 
parasite administration, and by investigating other means to increase control over the 
mouse innate immune response. The use of this IV model led us to identify, among several 
factors investigated, the effect of aging and that of inosine as significant in reducing 
inflammatory reactions, and therefore improving P. falciparum growth. Moreover, after 
using various strains of immunodeficient mice, we investigated, as others [14], the value of 
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the NOD/SCID/IL-2Rc-null mouse (NSG mouse) which, due to the knock out of the Ǆ-chain 
of the IL-2 receptor, has been shown to better tolerate a variety of transplanted human cells 
(Ito et al., 2002; King et al., 2007; Watanabe et al., 2007). The resulting new IV model based 
on NSG mice presents several advantages over previously available models. It offers greater 
reproducibility, with 100% of mice successfully grafted without the need for mouse-adapted 
parasites, consistent curves of parasitemia, and high levels of infection with up to 40–50% of 
total erythrocytes infected (Arnold et al., 2010). 
4. Strategic planning for the development of humanized mouse model 
4.1 Materials and methods 
4.1.1 Mice 
BALB/c, NOD/SCID and NSG mice are purchased from Charles River. Immunodeficient 
mice were kept in sterile isolators. They are housed in sterilized cages equipped with filter 
tops during the experimentation, and are provided with autoclaved tap water and a Ǆ-
irradiated pelleted diet ad libitum. They are manipulated under pathogen free conditions 
using laminar flux hoods.  
4.1.2 Human red blood cells 
Human whole blood is provided by the blood bank. Blood donors had no history of malaria 
and all the blood groups are used without observing any difference on parasite survival. 
Whole blood is washed three times by centrifugation at 900 ×g, 5 minutes at room 
temperature and buffy coat was separated in order to eliminate white blood cells and 
platelets. Packed huRBCs are suspended in SAGM (Adenine, Glucose and mannitol 
solution) and kept at 4°C for a maximum of 2 weeks. Before use huRBCs are washed three 
times in RPMI-1640 medium (Gibco/BRL, Grand Island, N.Y.) supplemented with 1 mg 
hypoxanthine per liter (Sigma, St Louis, MO) and warmed 10 minutes at 37°C. 
4.1.3 Parasites 
P. falciparum lines 3D7, UPA, and K1 are employed in the study, along with clinical isolates 
taken from a patient at Bichat Hospital, Paris (which was used the day after being sampled). 
The Uganda Palo Alto (UPA) strain employed is the Palo Alto Marburg line, used for all the 
experiments conducted. Parasite cultures are not synchronized and therefore a mix of 
various developmental stages was injected to infect mice. Parasites are maintained under in 
vitro conditions at 5% hematocrit at 37oC in a candle jar in complete culture medium (RPMI-
1640 medium (Gibco/BRL), 35mM HEPES (Sigma), 24mM NaHCO3, 10% albumax 
(Gibco/BRL) and 1mg of hypoxanthine (Sigma) per liter. Parasite samples are 
cryopreserved using the glycerol/sorbitol method (Rowe et al., 1968). The cultures are 
controlled for mycoplasma contamination by using polymerase chain reaction (PCR) 
technique. A non-lethal rodent parasite strain Plasmodium yoelii XNL1.1 is preserved in 500μl 
aliquot of cryo-preserving buffer at -80°C at 22% parasitaemia. The strain is thawed at room 
temperature, diluted twice in RPMI-1640 medium followed by the injection of 50 × 106 
parasite directly into the mice.  
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5. Protocols to control residual innate immunity 
5.1 (I.P. Protocol)  
5.1.1 Immunomodulatory agents to suppress innate immunity  
Numerous attempts have been made to increase the success rate of the grafting of infected 
RBC. Un-sized dichloromethylene diphosphonate (Cl2-MDP) encapsulated in liposome (clo-
lip) (provided by N. Van Rooijen, Amsterdam, The Netherlands) is injected through 
intraperitoneal (i.p.) route in order to reduce the number of tissue MP, as described 
previously (van Rooijen and van Kesteren-Hendrikx, 2003). The anti-PMN monoclonal 
antibody NIMP-R14 (Lopez et al., 1984) is purified from a hybridoma. Its activity is 
compared to that of two other anti-PMN monoclonal antibodies: RB6-8C5 (purified from the 
hybridoma) and 1A8 (BioXcell, Lebanon). The NIMP-R14 monoclonal antibody is used in all 
the studies, unless specified. Various agents (from Sigma) (Table 1) are used to further 
reduce innate immunity such as dexamethasone (1-5 mg/kg/day), TGF-ǃ (100 ng -  
1 μg/day) (PeproTech, Rocky Hill, NJ), cyclophosphamide (75 mg/kg/day), cisplatinium 
(1-10 mg/kg/day), and TMǃ-1 monoclonal antibody that targets NK cells (1 mg/kg/day).  
Expertiments Performed Using I.P. Protocol With Vaious Immunomodulatory Reagent
Protocol tested Dose 
Nb of 
mouse 
% of sucrose(more 
than 2 days 
Paracitemia length 
average (days) 
Best parasitemia 
(days) 
DSMO 5 % 18 88.8 7.18 12 
TGFβ 100 ng/day 17 23.5 7.25 8 
100 
µg/day 
3 66.6 10 13 
Splenctomy  5 60 7 10 
Cyclophopshamide 
75 mg/Kg 7 100 7.6 9 
50 mg/Kg 12 41.6 6.8 9 
Coinfection P.Chabaudi 
P.Falciparum 
 7 71.42 11 24 
Coinfection P.Yoellii 
P.Falciparum 
 52 90.24 11.09 34 
NAC 
100 
mg/Kg 
25 56 11.07 19 
Vitamine E 
200 
mg/kg 
13 77 8.25 34 
Trolox 4 mg/Kg 5 60 3.85 6 
Anti-NK(TMBβ-1) 1 mg 15 53.3 4.12 8 
Futhan 
200 
µg/day 
4 50 2.75 4 
Bleeding  20 35 7.42 14 
P.Falciparum with various 
amount 
0.3 2 100 2 2 
1% 2 100 4 4 
5% 2 100 5.5 6 
7% 2 100 4 4 
10% 2 100 5.5 6 
pABA 
400 
mg/Kg 
4 100 4.5 5 
Folinic acid mg/Kg 4 100 4.5 5 
Coinfection P.Chabaudi and P.Yoellii, NAC and Vitamine E seem to have a beneficial effect in P.Falciparum  
survival; however results are very heterogeneous form one mouse to other and from one experiment to other 
one  
Table 1. Various immune suppressants to control innate immunity 
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The effect of splenectomy and of irradiation (100 - 300 cGy) is also tested. Other experiments 
that evaluates the addition of metabolic agents such as pABA (400 mg/kg/day), and folinic 
acid (400 mg/kg/day), or of antioxidants, such as vitamin E (20 mg/kg/day; Nepalm, 
Cenexi, Fontenay-sous, France), N-acetyl cysteine (100 mg/kg/day), trolox (4-100 mg/kg 
/day), 8-aminoguanidine (100 mg/kg/day).  
5.1.2 Chemical immunomodulation protocol and mouse infection 
A previously described immunomodulation protocol (Badell et al., 2000), modified as 
described in (Moreno et al., 2006) is employed. On day -13, each mouse receives a dose of 10 
mg/kg of mAb NIMP-R14 by i.p. injection. On day -12, each mouse receives 0.2 ml of the 
suspension of clo-lip by the same route. On days -9, -6, -3 each mouse receives 0.5 ml of 
huRBCs i.p. mixed with a dose of 10 mg/kg of mAb NIMP-R14 and 0.2 ml of clo-lip. On day 
0 mice are infected with 50µl huRBCs parasitized by P. falciparum at a parasitaemia of 1% (all 
the developmental forms, i.e. trophozoite, schizont and rings, were present) mixed with a 
dose of 10 mg/kg of NIMP-R14 antibody. Afterwards, a dose of 10 mg/kg of antibody 
NIMP-R14, 0.2 ml of clo-lip and 0.5 ml of huRBCs is injected i.p. at 3 day intervals, until the 
end of the study. The infection is followed-up by daily Giemsa stained thin blood films 
drawn from the tail vein.  
 Means to control Innate Immunity
Infection
Blood 0.6 mL (60 % 
hematocrit) + clo-Iip 
+ NIMP-R14
Blood 0.6 mL (60 % 
hematocrit) + clo-Iip 
+ NIMP-R14
-13   -12   -11  -10  -9 -8 -7  -6  -5  -4 -3 -2 -1 0   1  2  3   4  5   6   7  8   9    10    11 
Clo-α PMN lip 250 
μg 0.2 mm 
 
Fig. 2. Schematics of intraperitoneal immunomodulation protocol  
5.2 Protocol for intravenous injection  
5.2.1 Mouse infection and immunomodulation protocol  
NOD/SCID mice are retro-orbitally injected with 400 µl huRBCs every 3 days to ensure a 
satisfactory proportion of huRBCs (i.e. chimerism), at the time of infection (≈ 60%). 
Simultaneously, 0.1 ml of un-sized dichloromethylene diphosphonate (Cl2MDP) 
encapsulated in liposome (clo-lip) (provided by Nico Van Rooijen) diluted in 0.4 ml RPMI is 
intraperitoneally injected. Four injections at 2-3 day intervals are given before parasite 
infection. At the time of the fifth injection, mice are retro-orbitally injected with 300 µl of a P. 
falciparum infected huRBCs suspension in RPMI at a parasitaemia of 1% (all the 
developmental forms, i.e. rings, trophozoites and schizonts were present). After infection 
huRBCs and clo-lip are supplied every 3 days as described for the pre-infection step. In 
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some experiments, 250 mg/kg of inosine (Sigma) is injected intraperitoneally every day as 
the half-life of inosine is very short (Mabley et al., 2009). In experiments using NSG mice the 
protocol has been adopted in order to achieve varying levels of adequate huRBCs chimerism 
and to avoid overloading the mice. As such, different amounts of blood are employed, and 
either 200, 400, 550 or 750 µl huRBCs are injected 3 times per week (i.e. Monday, Wednesday 
and Friday) mixed with 250 µl human AB serum, as it has previously been described that 
human serum improves huRBCs survival in immunocompromised mice (Angulo-Barturen et 
al., 2008); 4 injections are done prior to infection, and clo-lip is injected as described above. The 
infection is followed-up by daily Giemsa stained thin blood films drawn from the tail vein. 
5.2.2 Haematological parameters and grafting of P. falciparum-huRBCs 
The study blood samples are collected from mice retro-orbital sinus on heparin. Various 
haematological parameters such as haematocrit, leukocyte number and phenotype (Ly-6C 
APC, Ly-6G APC (Miltenyi Biotec, Germany), CD115 PE, CD43 FITC, CD62L FITC, CD11b 
FITC, DX5 FITC, CD122 PE (BD Biosciences, UK) in peripheral blood samples were 
monitored, as well as the phenotype characterization of monocytes (CD11b+,CD115+), 
inflammatory monocytes (CD43-, CD62L+, Ly-6C+), PMN (CD11b+, ly6G+), and natural 
killer cells (DX5+, CD122+). Total leukocyte number (leukocytes/μl blood) is evaluated by 
lysing 20μl of total blood with BD FACS™ Lysing solution, and counting on Malassez 
haematocytometer. Since successfully grafted mice have a significant, but variable, 
percentage of huRBCs in their peripheral blood, parasitaemia in mice is expressed as the 
overall percentage of P. falciparum infected RBCs among total RBCs, i.e. both human and 
mouse RBCs observed on thin blood smears. In addition, the peritoneal blood parasitaemia 
is measured on the smears drawn from the peritoneum.  
Blood samples drawn from mice are used to determine the percentage of huRBCs in mouse 
peripheral blood at regular intervals by flow cytometry on a FACScalibur (BD biosciences) 
using FITC labeled anti-human glycophorin monoclonal antibody (Dako, Denmark). 
5.2.3 Mouse cell isolation 
In NOD/SCID mice inflammation is induced by IP injection of 1ml 3% thioglycolate (Sigma) 
diluted in sterile PBS. 4-5 days after, the peritoneal cavity is washed with HBSS without 
Ca++ and Mg++. The collected cells are washed twice in RPMI supplemented with L-
glutamine, Penicillin (100U/ml), Streptomycin (100ug/ml), and 10% Fetal Calf Serum (FCS) 
and seeded at 3x105 per well in a 96-well culture plate. Cell suspensions of splenocytes are 
prepared in cold RPMI 1640 medium supplemented with 10% FCS and filtered on a 100 µm 
cell strainer to remove debris. Erythrocytes are lysed with ACK lysis buffer, and the 
splenocytes are washed 2 times with RPMI supplemented with 10% FCS and seeded at 3x105 
per well of a 96 well culture plate. 
5.2.4 Cytokines/chemokine/chemiluminesence assay  
100 µl blood samples are collected from the retro-orbital plexus with a Pasteur pipette, and 
sera are stored at -80°C. Conditioned media obtained after 16h stimulation of peritoneal cells 
and splenocytes with lipopolysaccharide (LPS, 1 µg/ml) (Sigma) are stored at -80°C. 
Cytokines and chemokines (IL-6, MCP-1, IFNǄ, TNFǂ, IL-12p70 and IL-10) are quantified 
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using the BDTM Cytometric Bead Array mouse inflammatory kit (BD biosciences) following 
the manufacturer’s recommendations on a FACScalibur (BD biosciences).  
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Fig. 3. Development of NSG-IV (NOD/SCIDIL2RǄ-/-) model: schematic of 
immunomodulatory protocol  
Since production of reactive oxygen intermediates (ROI) closely mirrors the state of 
activation of macrophages and polymorphonuclear cells, luminol dependent photometric 
assay is used to measure Reactive Oxygen Intermediates (ROI). Blood samples are collected 
from NOD/SCID mice, washed with HBSS with freshly added Ca++ and Mg++. Washed 
blood is diluted 1/10 in HBSS and 90 µl blood were added to each well in a 96 well plate 
(Nunc, Denmark) and incubated for 30 minutes at 370C after adding 10 µl PMA (final 
concentration 1 µg/ml) to stimulate the cells. 50µl of luminol (final concentration 200 
µg/ml) solution are added immediately before measuring emissions. 
5.2.5 Analysis of deep-seated organs for parasite differential count  
NSG mice are used for the comparison of parasite differential counts in the peripheral 
blood, with that in deep-seated organs. Four mice are infected with UPA strain, and when a 
parasitaemia of >10% is reached a thin smear from peripheral blood is drawn before killing 
the mouse, and harvesting its organs. Kidney, Liver, Spleen, Lung, and Brain are removed 
from each mouse. Parasite content is assessed from blots made by repeatedly spotting 
sections from each organ. These slides are then stained with Giemsa. The last blots taken, 
are considered to be the most representative of the parasite content in the organ’s vascular 
bed, and are examined at 1000x magnification to perform differential counts of each stage (> 
200 parasites from each organ counted). 
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6. Anticipated results 
The present protocols illustrate an improvement of the mice with genetic deficiencies in 
adaptive immunity for successful grafting of human cells or pathogens to study human 
biological processes in vivo. Since non-adaptive immunity received little attention, we have 
deployed our efforts to study innate defences, responsible for the substantial control of P. 
falciparum and highlighted some of the remaining limitations on the development of the 
optimal humanized mouse. In addition, numerous attempts were made to enhance the 
success rate of infected huRBC by employing various immunomodulatory agents 
intraperitoneally to further suppress the residual innate immunity. This study came up with 
some conclusions such as, 1) stable parasitaemia with only a subset of mice 2) parasite 
clearance and P. falciparum induced inflammation are correlated 3) P. yoelii induces less 
inflammation than P. falciparum 4) huRBC, and the anti-inflammatory agents, induce low 
grade inflammation. 5) repeated administrations of huRBC, clo-lip and anti-PMN reduce 
inflammation and improve HuRBC grafting 6) MO/MPs are critical in controlling P. 
falciparum and huRBC grafting in NOD/SCID. A strong pro-inflammatory effect of the 
parasite itself and poor understanding of migration of infected and uninfected huRBC into 
blood stream across the peritoneum and subsequently, uneven distribution of huRBC are 
two barriers to achieving an improved, workable humanized mouse model. The results 
obtained by the IP protocols indicate that the SCID mice to study human biological 
processes in vivo need to be carefully explored and that further attempts are required to 
address the remaining limitations such as residual innate immunity and route of delivery of 
huRBC to create an optimized humanized mouse model. 
The complex biological processes often require in vivo analysis of human cells: humanized 
mice or mouse-human chimeras have been developed to meet this requirement, however, 
with low percentage of infectivity and reproducibility supporting a long standing 
parasitaemia only in a proportion of animals. We have obtained improved parasitaemias 
based on intravenous delivery of huRBC and P. falciparum instead of the intraperitoneal 
route (IP) by testing various immunosuppressive drugs.  
In essence the genetic background has also played an important role to optimize the 
humanized mouse model. The intravenous mouse model (NSG-IV) shows the role of ageing 
and inosine in controlling P. falciparum induced inflammation. The success of humanized 
mouse (NSG mice) model, with IV delivery of huRBC and P. falciparum in clo-lip treated 
(immunosuppression of macrophages) mice, was 100% in terms of infectivity and 
reproducibility. Synchronization, partial sequestration and receptivity to various strains of 
P. falciparum without preliminary adaptation are some of the lucrative features of the 
developed mouse model which is reliable and more relevant, and better meet the needs of 
biomedical translational research. 
7. Conclusion 
In conclusion, the chapter demonstrates that the careful selection of mice with combined 
deficiencies of adaptive and innate immunity, and the better control of innate immune 
defenses by improving immunomodulatory protocols and using anti-inflammatory 
substances, could provide a reproducible, long lasting and straightforward mouse model of 
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P. falciparum infection. This model may be further used to obtain malaria parasites that 
present a high level of resistance to different anti-malarial drugs such as artemisinin in vivo 
and in vitro. Interestingly, the same model could be also used to test the efficacy of new 
drugs, and in particular could be used to screen novel drugs for their effectiveness against 
ART resistant P. falciparum parasites 
8. Abbreviations 
NOD- Non-Obese Diabetic; SCID-Severe Combined Immunodeficiency; IL2Rγ- Interleukin-2 
Receptor Ǆ-chain; NK- Natural Killer; PBMCs: Peripheral Blood Monocytes; HSCs: 
Hematopoietic stem cells; Rag-Recombination-Activating Gene; IL-Interleukin; huRBCs—
Human Red Blood Cells; PMN-Polymorphonuclear; SAGM- Adenine, Glucose and 
Mannitol solution; CL2MDP- Dichloro-Methylene-Diphosphonate; NSG-NOD scid gamma; 
TGF-Tumor Growth Factor; APC-Antigen Presenting Cell; FACS- Fluorescence Activated 
Cell sorting; FCS- Fetal Calf Serum; FITC- Fluorescein isothiocyanate, phorbol-12-myristate-
13-acetate (PMA) 
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